Access cutting-edge chronic kidney disease (ckd) treatment through this phase 2 clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Little Rock location
Preparing your pre-screening questions…
Access chronic kidney disease (ckd) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic kidney disease (ckd) treatment provided free
Check if you qualify for this chronic kidney disease (ckd) clinical trial in Little Rock, AR
No-Cost Study Care
Local to Little Rock
Convenient for AR residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD). Inflammation is thought to contribute to the risk of heart disease which is the leading cause of death in patients with CKD. Decreasing inflammation may decrease the risk of heart disease. The main questions it aims to answer are: * Why are patients with CKD at increased risk for heart disease and how to reduce that risk in the future. * If there could be new treatment options for managing inflammation in blood of patients with CKD. Researchers will compare Ticagrelor to a Placebo (a look-alike substance that contains no drug) to see if ticagrelor decreases inflammation in adult patients with CKD. A comparator (control) group not receiving the drug/placebo will consist of adults without CKD. Participants with CKD will: * Take ticagrelor 90 mg or placebo orally twice daily for 42 days * Visit the clinic once every 2 weeks for checkups, tests, and bloodwork * Participation will last approximately 12 weeks Participants without CKD (control group) will visit the clinic twice (7 weeks apart) to provide information and bloodwork. Participation will last approximately 7 weeks with additional optional visits.
Sponsor: University of Arkansas
Yes, this clinical trial (NCT07911124) has an active research site in Little Rock, AR that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for chronic kidney disease (ckd) treatment options in Little Rock, AR, this clinical trial (NCT07911124) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic kidney disease (ckd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all chronic kidney disease (ckd) clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in Little Rock — not just this study.
Browse Ankylosing Spondylitis Trials in Little Rock →